Reply  by Baracchini, Claudio & Ballotta, Enzo
LETTERS TO THE EDITOR
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nRegarding “Predictors of neck bleeding after eversion
carotid endarterectomy”
We noted with interest the recent study by Baracchini et al,1
which reports a single-center, single-surgeon experience of
eversion carotid endarterectomies (CEA) and factors associated
with increased perioperative bleeding complications, including
re-exploration for bleeding. The study concludes that preopera-
tive treatment with clopidogrel, when used either alone or com-
bined with aspirin was associated with an increased incidence of
bleeding. The authors additionally conclude that aspirin and ticlo-
pidine, when used alone preoperatively were also associated with
an increased incidence of neck hemorrhage following CEA. Re-
view of the study sample, however, reveals that only 110 patients
were taking clopidogrel alone within 1 day of surgery and that only
an additional 10 patients were taking combined therapy (clopi-
dogrel  aspirin). Furthermore, only 95 patients were taking
aspirin alone at the time of CEA, making definitive conclusions
regarding these commonly used antiplatelet agents more difficult.
By comparison, in a recent study by the Vascular Study Group
of New England,2 we evaluated 5264 carotid endarterectomies,
performed by 66 surgeons treated at 15 academic and community
centers. We found that preoperative aspirin (asa; n  3823),
clopidogrel (n  147), or dual antiplatelet therapy (asa  clopid-
ogrel; n  708) use was not associated with any increase in
re-exploration for bleeding after CEA (asa 1.2%, clopidogrel 0.7%,
asa  clopidogrel 1.4%; P  .84).2 Based on this data, we do not
believe that aspirin or clopidogrel increases serious bleeding com-
plications and it remains our practice to routinely perform CEA in
patients taking antiplatelet therapy at the time of surgery, for which
there is sufficient evidence from both randomized controlled trials
and our study group to justify therapy given their impact on
reducing stroke.3-6
The different conclusion reached by Baracchini et al could also
relate to their nonuse of protamine to reverse heparin during CEA,
potentially amplifying bleeding risk if antiplatelet agents are also
being used. Our data has previously shown a significant decrease in
re-exploration for bleeding after CEA (n 4587) when protamine
is used, independent of antiplatelet agents (protamine 0.64% vs no
protamine 1.66%; P  .001).7
Accordingly, we believe that recent studies support the safe
use of both antiplatelet therapy at the time of CEA and the use of
protamine to reverse heparin intraoperatively.
David H. Stone, MD
Philip P. Goodney, MD
Brian Nolan, MD
Section of Vascular Surgery
Dartmouth-Hitchcock Medical Center
Lebanon, NH
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We thank Drs Stone, Goodney, and Nolan for expressing their
nterest in our article and giving us the opportunity to reply to their
etter and further clarify some issues of our study.1
Drs Stone, Goodney, and Nolan believe that the number of
ur patients continuing clopidogrel (n 110) or aspirin (n 95)
r both (n 10) to the day before carotid endarterectomy (CEA)
s too small to draw any definite conclusions about the risk of neck
leeding after CEA. Since our preoperative protocol includes the
iscontinuation of any type of preoperative antiplatelet therapy for
week before surgery, it was already expected that only a small
ercentage of patients would violate this protocol, mainly for their
wn omission. Therefore, the statistical analysis was performed on
his portion of our patient population, and our results show that
reoperative treatment with clopidogrel, when used either alone or
ombined with aspirin, was associated with an increased incidence
f bleeding.
In agreement with Drs Stone, Goodney, and Nolan, we are
uite aware that our results do not represent a universal law and
annot be exported before a large multicenter prospective trial
efinitely clarifies this issue. However, we do believe that our
esults are as significant as those reported in the recently published
tudy by the Vascular Study Group of Northern New England,2 in
hich clopidogrel was not associated with major bleeding compli-
ations. In fact, that observational study has also several limits: (1)
t is not a randomized comparison of patients treated with clopi-
ogrel versus untreated patients; (2) patients’ baseline characteris-
ics before and during CEA are not reported; and (3) the results are
ot controlled for individual surgeon or center effects. Further-
ore, the primary endpoint of that study2 was postoperative
leeding requiring reoperation, while in our investigation, we
ncluded any clinical signs of neck bleeding after CEA, warranting
r not warranting surgical re-exploration. We believe that the
ifferent conclusions reached in the two studies could be related to
hese differences.
With regard to the use of protamine to reverse the effects of
eparin during CEA, we are aware of and we quoted the Stone et
l recently published article showing that protamine reduces bleed-
ng complications without increasing the stroke risk.3 However,
e are still reluctant in applying those results in our everyday
linical practice because of several intrinsic limitations present in
he study by Stone et al,3 mainly due to the nonrandomized
ontrolled nature of the trial and, surprisingly, to the absence of
eurologists involved in the diagnosis of stroke. No information is
iven on how that diagnosis was reached, and certainly cerebral
agnetic resonance was not performed in all patients in order to
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Volume 55, Number 3 Letters to the Editor 891exclude “silent” strokes, a predictor of future cognitive deteriora-
tion.
In conclusion, based on the analysis of nearly 1500 CEAs, our
study demonstrates that preoperative treatment with clopidogrel,
particularly when it is continued to the day before surgery, seems to
be associated with a higher risk of neck bleeding after CEA,
requiring re-exploration in most cases.1 Larger studies are war-
ranted to confirm our findings and prevent this feared surgical
complication.
Claudio Baracchini, MD
Department of Neurological Sciences
University of Padua School of Medicine
Padova, Italy
Enzo Ballotta, MD
Vascular Surgery Section
Geriatric Surgery Clinic
Department of Surgical and Gastroenterological Sciences
University of Padua School of Medicine
Padova, Italy
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Regarding “Impact of cilostazol after endovascular
treatment for infrainguinal disease in patients with
critical limb ischemia”
We were delighted to read the recent publication of the work
by Soga et al1 regarding the use of cilostazol in patients with critical
limb ischemia (CLI). To our knowledge, this is the first and
extremely valuable multicenter, retrospective analysis study that
investigates the effects of cilostazol in this cohort of patients.
In our own practice at Barts and The London NHS Trust in
the United Kingdom, we have not used cilostazol to treat patients
with CLI. In England, cilostazol is currently only licensed for use
in patients with claudication but not CLI.2 In Scotland, however,
its use is not licensed at all!
Recently, the National Institute for Health and Clinical Ex-
cellence (NICE), an independent organization responsible for
providing national guidance on promoting good health and pre-
venting and treating ill health in England, decided not to recom-
mend the use of cilostazol for treatment of peripheral vascular
disease for any indication.3 This decision is based on a cost- and
clinical-benefit analysis of National Health Service (NHS) re-
sources. With this higher authority not recommending the use of
cilostazol in patients with claudication and no CLI, in addition to
the current worldwide financial situation, do the authors think the
use of cilostazol in patients with CLI is cost-effective? We noticed
that there is no cost analysis in their study. Did they find a financial
advantage for the use of cilostazol?
This information regarding costing is vital for rationalization
for us to implement the use of cilostazol in this cohort of patients
into our current practice in the United Kingdom. Thiva Dindyal, BSc, MBBS, MRCS (Edin), MRCS (Eng)
onstantinos Kyriakides, MD, FRCS
arts and The London NHS Trust
arts and The London School of Medicine and Dentistry
irculatory Sciences Clinical Academic Unit
ascular and Endovascular Surgical Services
he Royal London Hospital
hitechapel, London, United Kingdom
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We conducted a multicenter retrospective study to evaluate
he economic effectiveness of cilostazol (the purchase price of 200
g cilostazol in the United States is $4.0-$5.2 US dollars) in
atients with critical limb ischemia (CLI), with the understanding
hat this study had many limitations. The efficacy of cilostazol was
etrospectively evaluated in 618 patients who had developed CLI
or the first time.1 No significant difference in overall survival was
ound, but major amputation was significantly decreased in the
ilostazol-treated group. To evaluate the economic effectiveness of
ilostazol, it was assumed that administration of cilostazol did not
hange the mortality and provided a 50% risk reduction in the rate
f major amputation of 20% in 5 years. If 500 of 1000 patients with
LI treated with endovascular therapy are treated with aspirin and
ilostazol and the other 500 with aspirin alone, major amputation
ill be required in 100 patients in the aspirin group and 50 in the
spirincilostazol group over 5 years; therefore, the number
eeded to treat value is 10 (50 of 500). The drug price of cilostazol
t 200 mg per person is 379 yen/day ($4.7 US dollars/day; $1 
80), 138,335 yen/year ($1729 US dollars/year), and 691,675
en/5 years ($8646 US dollars/5 years). Assuming no deaths, it
akes 350 million yen ($4.3 million US dollars) to treat 500
atients with cilostazol for 5 years. Therefore, it is estimated that it
akes approximately 7 million yen ($90,000 US dollars) to prevent
ajor amputation in a patient with CLI. However, the mortality is
ctually around 11% per year, which gives an estimate of 4 to 5
illion yen (%50,000-$62,500 US dollars) to prevent major am-
utation in a patient with CLI. The mean total hospitalization cost
as 3.41 million yen ($43,000 US dollars) and the additional
ospitalization cost due to major amputation was 730,000 yen
$9100 US dollars) in 40 patients who were randomly extracted
rom this study. In patients who did not undergo major amputa-
ion, a hospitalization cost of 390,000 yen ($4900 US dollars) was
dded due to minor amputation and wound treatment. The hos-
italization cost in patients with major amputation was 340,000
en ($4250 US dollars) higher ( cost) than that in patients
ithout major amputation. Although the costs were not the same
n all patients, these results suggest that cilostazol decreased the
ospitalization cost when administered to patients with CLI. The
ealth care costs at other hospitals and the expense of hospital visits
ere not included and these costs should also be considered.The costs estimated in this study are only an approximation.
he economic validity of administration of cilostazol to patients
